Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday November 18, 2009

DrStockPick.com Stock Report!

PWRM, Power 3 Medical Products Inc, PWRM.OB

PGCX, Pangenex Corporation, PGCX.PK

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical PWRM continued to rally for the 2nd day in a row closing at $0.17 hitting a 52 week high of $0.22 on the way. PWRM’s volume has also performed trading over 36 million shares today by the time the closing bell rang.

Those of you who put

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

…

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

…

Nov. 12, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 12 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) is the keynote presenting company at the founders’ celebration of consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The celebration will be attended by over 200 founders and guests of Regeneca International from across the United States. It will be hosted at the prestigious Balboa Bay Club in Newport Beach, California. Vivakor’s Chairman, Matt Nicosia and CFO, Ed Corrente will both be attending the event.

Event attendee, Dr. Brian Scott , a Regeneca advisory board member and nationally recognized wellness expert, was particularly pleased to learn of Vivakor’s role in the event. “As a healthcare provider and speaker on issues regarding wellness and longevity, it is refreshing to hear the perspective of a company, doing business internationally, which can provide a particular focus on products which extend the length and

Power3 Medical Products, Inc.

(Public, OTC:PWRM)

The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Michael Sklar. He has been studying the markets for several years now with a focus in undiscovered Bio-Pharm companies.

About

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company

Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.

Moreover, there will be huge profit opportunities, in many enabling technologies, for those who invest accordingly. And today I’m going to tell you about a company that will hand you your best chance to make a transformational fortune.

We know that many current treatments work on some people, yet not others. Some drugs are safe for many people, but have dangerous side effects for others. This is because all of us have individual differences in our genetic code based on heredity and environment. Even slight differences can lead to very different reactions to medications.

This has created serious regulatory problems. Drugs are denied regulatory approval not because they do not work, but because some

BSX, Boston Scientific Corporation

PWRM, Power 3 Medical Products Inc, PWRM.OB

PennyOmega.com Watch List!

PennyOmega.com Watch List ! for Tuesday July 21, 2009

Our Picks at PennyOmega.com for Tuesday July 21, 2009 are:

**************************************************************

BSX, Boston Scientific Corporation

BSX operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide.

BSX’s products help physicians and other medical professionals improve the patients quality of life by providing alternatives to surgery.

*To consider about BSX

Today, after Closing Bell, BSX announced financial results for the second quarter ended June 30, 2009.

Net sales for the second quarter of 2009 were $2.074 billion, as compared to net sales of $2.024 billion for the second

On June 29, Celera Corp. (CRA) announced that it has licensed five compounds to drugmaker Bayer Schering Pharma AG for detection and identification of tumors.

Although the terms of the deal were not disclosed, Celera is entitled to receive a one-time fee for exclusive access to the five targets. Additional payments are due upon achievement of certain development and commercial milestones. Celera will also receive royalties on sales if the products are commercialized.

Competitive Landscape

Celera, formerly Celera Genomics Group, has significant capabilities and expertise in proteomics, bioinformatics, and genomics. Its diagnostic products business competes with companies in the U.S. and abroad that are engaged in the development and commercialization of products and services that provide genetic information. These companies may develop products or services that are competitive with, and could be more effective and/or cost-effective compared to the diagnostic products offered by Celera or its

Chicago, IL - June 24, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: LabCorp (LH), Monogram Biosciences, Inc. (MGRM), Pfizer (PFE), Quest Diagnostics (DGX) and Myriad Genetics (MYGN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday's Analyst Blog:

Monogram Acquired by LabCorp

LabCorp (LH) and Monogram Biosciences, Inc. (MGRM) announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55

Lixte Biotechnology [[LIXT.OB]] was founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to become a cancer drug discovery operation.

Lixte engages in the discovery of anti-cancer compounds to improve the treatment of malignancies with few effective treatment options, such as certain types of brain cancer. Other areas of early-stage, preclinical drug discovery include: (1) improved anti-fungal treatments for patients with compromised immunity (e.g. HIV/AIDS, bone marrow transplantation); (2) neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease; and (3) biomarker assays for diagnostic and prognostic applications in the detection of disease and monitoring of treatment effectiveness.

Since Lixte is a development-stage company which does not generate any revenue, the ability to obtain financing to fund research and drug discovery operations will be a key factor this year. The Company estimates minimum funding requirements of $750,000 for this year, which will